Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort

Abstract

Background: Psychotropic medication is widely prescribed in clinical practice for the management of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD). However, there have been few pharmaco-epidemiological studies or studies conducted in a natural setting on the real use of antidepressants in AD. The aim of this survey was to assess the prevalence of antidepressant use in AD and to identify the clinical factors associated with antidepressant prescription.Methods: REAL.FR is a four-year, prospective, multi-center study. Baseline data including demographic characteristics, clinical variables and drug intake were obtained. Depressive symptoms were determined using the Neuropsychiatric Inventory (NPI).Results: A total of 686 AD patients were included. Antidepressant treatment was prescribed for 34.8% of patients. Clinically significant depressive symptoms (NPI ≥ 4) were observed in 20.5% of the total population. Although depressed subjects were significantly more likely to be treated with antidepressants than non-depressed subjects (p<0.0001), only 60% of depressed subjects overall were prescribed an antidepressant. In multivariate analysis, clinically significant depressive symptoms were associated with antidepressant prescription although this result was only observed in subjects without a previous history of depression.Conclusions: The available data on antidepressant efficacy in BPSD other than depression (in particular, agitation, aggression and, occasionally, psychotic symptoms) do not influence prescription choices. Depressive symptoms may be taken more seriously in the absence of a previous history of depression, leading to increased antidepressant prescription rates in individuals presenting with depression for the first time.

Depressive Symptoms in Chinese-American Subjects with Cognitive Impairment

“…These findings are consistent with prior studies indicating that depression is a common neuropsychiatric symptom in the setting of MCI and dementia, and the frequencies for depression we observed are within the broad range of prevalence estimates in these conditions, which range from 20 to 50% (4, 6, 8, 27–35). However, due to a lack of similar studies, it is difficult to directly compare the results from the current analysis to findings from previous authors.…”

Antidepressant use among persons with recent-onset rheumatoid arthritis: a nationwide register-based study in Finland

“…The presence of a neurological disease (mainly Alzheimer's) doubled the rate of antidepressant initiations. This is in line with the increased prevalence of antidepressant use in Alzheimer's disease (38,39). The presence of diabetes, cardiovascular, or pulmonary diseases increased the probability of antidepressant initiations by 20% to 30%.…”

Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting

“…This figure is not high in naturalistic cohorts, because several studies show that AD patients have a large comorbidity with depression, ranging from 20% to 30%. Among large European naturalistic AD cohorts, a 24% depression rate was described in one study47 and in another study anti-depressants were prescribed to 34% of the patients 48. We know that the patients receiving antidepressants at baseline did not drop out to a greater extent than the ones without this treatment.…”